Similarly, entrectinib and repotrectinib, which also inhibit Receptor tyrosine kinase 1 ROS1, are approved for ROS1-mutated non-small cell lung cancer; however, it is not approved under tumor-agnostic indications. Here, ROS1 is linked to non-small cell lung carcinoma.